Sunshine Biopharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steve N. Slilaty
- Full Time Employees
- 50
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 333 Las Olas Way Fort Lauderdale FL United States of America 33301
- IPO Date
- Feb 15, 2022
- CIK
- 0001402328
- Website
- sunshinebiopharma.com
- Similar Companies
- Business
- Sunshine Biopharma, Inc. (NASDAQ:SBFM) operates as a pharmaceutical company focused on the research, development, and commercialization of life-saving medicines across oncology, antivirals, and other therapeutic areas in the United States and Canada. Founded in 2006 and headquartered in Fort Lauderdale, Florida, the company conducts business through two segments: Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products; it markets approximately 70 generic prescription drugs in Canada via its wholly owned subsidiary Nora Pharma Inc., covering indications such as osteoporosis, cardiovascular disease, antipsychotics, antibacterial infections, hypertension, anti-inflammatory conditions, allergies, antibiotics, central nervous system disorders, diabetes, urology, antifungals, antimalarials, oncology, gastroenterology, and anticonvulsants, including generics of Lipitor, Zithromax, Atacand, Proscar, Diflucan, and Prozac; it also offers OTC products under the Essential brand, such as Essential 9 amino acid capsules, Essential Calcium-Vitamin D supplements, L-Citrulline, and Taurine. In proprietary development, Sunshine Biopharma advances K1.1 mRNA as an mRNA-lipid nanoparticle for liver cancer, Adva-27a as a small-molecule chemotherapy for multidrug-resistant pancreatic and other cancers, and SBFM-PL4 (also referred to as PLpro protease inhibitor) as a small molecule for SARS coronavirus infections, supported by collaborations with the University of Arizona. Recent developments include the March 2025 acquisition of rights to two gastrointestinal drugs for the Canadian market, with generic Prucalopride (Resotran equivalent, 1mg/2mg tablets for chronic idiopathic constipation) already launched and the second planned within nine months, targeting a $200 million CAD submarket growing at 4.64% CAGR through 2034; launches of NIOPEG (Neulasta biosimilar) in July 2025, Everolimus (oncology) in April 2025, Lurasidone (schizophrenia), Gabapentin (neuropathic pain), Pravastatin (cholesterol), Doxycycline (STD/acne/Lyme), Domperidone (cancer nausea), and antibiotics in 2025; acquisition of marketing rights for two new antibiotics in March 2025; a $2.46 million registered direct offering in April 2025; $5 million Bitcoin treasury allocation in October 2025; and advancement of new protease inhibitors with the University of Arizona in October 2025, alongside reporting fiscal 2024 revenue of $34.9 million (up 45% year-over-year) and first-quarter 2025 revenue growth of 18%. Sunshine Biopharma also operates Sunshine Biopharma Canada Inc. for OTC products and plans additional generic launches in 2025, including expansion to 15 new drugs.
Sunshine Biopharma and University of Arizona Publish Significant New Research Findings
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Down 35.0% in June
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)
Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)
Sunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment Technology
Why Sunshine Biopharma (SBFM) Stock Dropped After Hours Today
Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ Listing
Sunshine Biopharma Stock Rallies On Canadian Approval For Generic Amoxicillin
Sunshine Biopharma Receives Canadian Regulatory Approval for Generic Amoxicillin
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
Sunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior Year
Sunshine Biopharma (NASDAQ:SBFM) Trading Up 4.1% – Should You Buy?
Sunshine Biopharma Scores a Major Regulatory Win to Market Domperidone in Canada (NASDAQ: SBFM)
Sunshine Biopharma Gains FDA-Equivalent Clearance in Canada for Domperidone to Treat Cancer-related Nausea
Sunshine Biopharma Launches STD, Acne and Lyme Disease Therapy Doxycycline
Sunshine Biopharma Launches Cholesterol Fighting Medicine Pravastatin
Sunshine Biopharma is Proving That Riding Momentum is an Effective Strategy (NASDAQ:SBFM)
Sunshine Biopharma Proves Microcap Ambition Can Deliver Large-Cap Level Execution (NASDAQ: SBFM)
Sunshine Biopharma Allocates $5 Million for Investment in Bitcoin as Strategic Reserve Asset to Enhance Treasury Resilience